Simvastatin Can Injure Muscle At High Dose, FDA
The highest approved dose (80 mg) of the cholesterol-lowering drug simvastatin, is tied to higher risk of myopathy or muscle injury, including its most serious form rhabdomyolysis. This is particularly significant in the first 12 months of use, said the US Food and Drug Administration (FDA), who announced safety label changes yesterday. Patients are advised not to stop their medication without ...

FDA: Treatment With Angiotensin Receptor Blockers For High Blood Pressure Does Not Increase Risk Of Cancer
The U.S. Food and Drug Administration today announced that a group of medications used to control high blood pressure, called angiotensin receptor blockers (ARBs), do not increase the risk of developing cancer in patients using the medications. In July 2010, the FDA reported that a safety review of ARBs would be performed after a published study found a small increased risk of cancer in patients ...

SEC adds insider trading charge vs FDA chemist
Federal regulators on Thursday expanded their civil insider-trading charges against a chemist with the Food and Drug Administration accused of using confidential FDA information on pending drug approvals to profit from trades of drug companies' stock.